Rockwell Medical, Inc. (NASDAQ:RMTI) Brokerage Rating Update - Investor Newswire Print

Rockwell Medical, Inc. (NASDAQ:RMTI) has been handed a rating of 2 on a consensus basis by Zacks Research. Using a simplified 1 to 5 scale where 5 represents a Strong Sell and 1 a Strong Buy, 4 analysts polled by Zacks had their ratings weighed into this average. In order to measure the direction of the analyst sentiment, the same analysts had a rating of 2 on the equity three months ago.

Sell-side analysts covering Rockwell Medical, Inc. (NASDAQ:RMTI) have a one year price average objective of $16.25 on the equity. The targets range from $4 to $26, according to the data from research firms surveyed by Zacks.

Earnings in Focus Analysts on the Street are anticipating Rockwell Medical, Inc. will report earnings per share of $-0.1 for the fiscal quarter ending on 2015-06-30. Estimates from 4 brokers were taken into consideration to arrive at this estimate. Looking ahead on a three to five year basis, Wall Street is expecting earnings of $25 per share on the stock. This is the best estimate according to Zacks for sales and earnings over that time span. Investors and analysts alike will be marking their calendars when Rockwell Medical, Inc. is expected to report earnings on 2015-07-30. The company will be trying to improve on the previous quarter’s numbers of $-0.07 for the quarter ending on 2015-03-31. The actual EPS was 30% away from what analysts had expected, or a $0.03 difference. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...